A next-generation manufacturing facility setting new global benchmarks
Located in Broadmeadows, CSL’s facility blends Pharma 4.0™ principles with sustainable design to transform plasma fractionation and production.
Built to increase access to plasma-derived therapies for people with immunodeficiencies, neurological conditions and severe burns, the facility features:
Advanced automation and robotics
Real-time production monitoring
Digital twin infrastructure
A hybrid and modular manufacturing platform
Fully paperless execution and continuous improvement systems
These innovations have increased plasma processing capacity nine-fold, enabling CSL to process more than 9 million litres annually, improve yields, and ultimately reach more patients around the world.
Proof of Victoria’s global competitiveness
CSL’s win is a powerful signal to global investors that Victoria offers the infrastructure, talent and innovation required to lead in biomanufacturing.
Victoria accounts for more than 40% of Australia’s pharmaceutical manufacturing output.
Global biotech firms have invested over $3 billion in Victoria in the past five years.
Melbourne delivers 60% of Australia’s pharmaceutical exports and is the country’s largest biotech ecosystem.
The state is home to more than 70% of Australia’s top pharmaceutical and medtech companies, supported by 90,000 life science professionals — the largest talent base in the nation.
Victoria also offers companies streamlined clinical trial processes, globally connected biomedical precincts, and one of the most established and trusted regulatory environments in the Asia-Pacific.
A proven location for end-to-end pharmaceutical innovation
In Victoria, companies can research, trial, manufacture and export pharmaceutical products from one of the most sophisticated biomedical ecosystems in the world.
This includes the Melbourne Biomedical Precinct in Parkville and more than 22 globally recognised research institutes — a powerful cluster driving advances from mRNA to regenerative medicine.
Ready to invest in a globally trusted location?
